AUSTIN, Texas, March 09, 2017 -- XBiotech Inc. (NASDAQ:XBIT) announced today it will host a conference call and live audio webcast on Thursday, March 16, 2017, at 8:30 a.m. Eastern Time, to provide an overview of its corporate and clinical activities. The call will encompass developments during the fourth quarter and year ended December 31, 2016.
Conference Call Information:
Interested participants and investors may access the conference call by dialing:
- 1 (844) 249-9385 (U.S.)
- 1 (270) 823-1533 (International)
- Conference ID: 81246237
A live audio webcast will also be accessible via the Investors section of the XBiotech website www.xbiotech.com. The webcast replay will remain available for 90 days.
A telephonic replay of the conference call can be accessed by dialing 1 (855) 859-2056 (U.S.) or 1 (404) 537-3406, and providing the Conference ID: 81246237. The telephonic replay will be available for 24 hours beginning at 11:29 p.m. Eastern Time on March 16, 2017.
About XBiotech
XBiotech is a fully integrated global biosciences company dedicated to pioneering the discovery, development and commercialization of therapeutic antibodies based on its True Human™ proprietary technology. XBiotech currently is advancing a robust pipeline of antibody therapies to redefine the standards of care in oncology, inflammatory conditions and infectious diseases. Headquartered in Austin, Texas, XBiotech also is leading the development of innovative biotech manufacturing technologies designed to more rapidly, cost-effectively and flexibly produce new therapies urgently needed by patients worldwide.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements, including with respect to the proposed offering of common shares, declarations regarding management's beliefs and expectations that involve substantial risks and uncertainties. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "would," "could," "expects," "plans," "contemplate," "anticipates," "believes," "estimates," "predicts," "projects," "intend" or "continue" or the negative of such terms or other comparable terminology, although not all forward-looking statements contain these identifying words. Forward-looking statements are subject to inherent risks and uncertainties in predicting future results and conditions that could cause the actual results to differ materially from those projected in these forward-looking statements. These risks and uncertainties are subject to the disclosures set forth in the "Risk Factors" section of certain of our SEC filings. Forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.
Contact Ashley Otero [email protected] 512-386-2930


Google Accelerates AI Infrastructure With Ironwood TPU Expansion in 2026
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital
Starlink Plans Satellite Orbit Reconfiguration in 2026 to Boost Space Safety
Samsung Signals Comeback With HBM4 Chips as AI Market Heats Up
Lockheed Martin Secures $92.8M AEGIS Sustainment Contract from U.S. Navy
Elon Musk’s xAI Expands Supercomputer Infrastructure With Third Data Center to Boost AI Training Power
Australia’s Modern Gold Rush: Hobby Prospectors Flock to Victoria’s Golden Triangle
Bain Capital Moves to Acquire Majority Stake in Echo Marketing
Boeing Secures Major $2.7 Billion U.S. Military Contract for Apache Helicopter Support
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions
Neuralink Plans Automated Brain Implant Surgeries and Mass Production by 2026
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro
Drugmakers Plan 2026 U.S. Price Increases on Over 350 Branded Medications Despite Political Pressure
Anghami Stock Soars After Strong H1 2025 Results, Revenue Nearly Doubles on OSN+ Integration 



